^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Immunoprint®

    Company:
    NeraCare
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over1year
    SkylineDx and NeraCare enter a strategic partnership to advance precision medicine for early-stage melanoma (Skyline Dx Press Release)
    "SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies bring lifesaving melanoma therapies to market...The agreement includes an exclusive co-development and licensing agreement for Immunoprint®. SkylineDx and NeraCare will work together to accelerate the development of Immunoprint®, while leveraging SkylineDx’s global network, and discovery and validation expertise."
    Licensing / partnership
    |
    Immunoprint®